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ichael Reed, MD,* Pascal Meier, MD,* Umesh U. Tamhane, MD,*
athy B. Welch, MS, MPH,† Mauro Moscucci, MD,‡ Hitinder S. Gurm, MD*
nn Arbor, Michigan; and Miami, Florida
bjectives We sought to compare the nephrotoxicity of the iso-osmolar contrast medium, iodixa-
ol, to low-osmolar contrast media (LOCM).
ackground Contrast-induced acute kidney injury (CI-AKI) is a common cause of in-hospital renal
ailure. A prior meta-analysis suggested that iodixanol (Visipaque, GE Healthcare, Princeton, New
ersey) was associated with less CI-AKI than LOCM, but this study was limited by ascertainment bias
nd did not include the most recent randomized controlled trials.
ethods We searched Medline, Embase, ISI Web of Knowledge, Google Scholar, Current Contents,
nd International Pharmaceutical Abstracts databases, and the Cochrane Central Register of Con-
rolled Trials from 1980 to November 30, 2008, for randomized controlled trials that compared the
ncidence of CI-AKI with either iodixanol or LOCM. Random-effects models were used to calculate
ummary risk ratios (RR) for CI-AKI, need for hemodialysis, and death.
esults A total of 16 trials including 2,763 subjects were pooled. There was no signiﬁcant differ-
nce in the incidence of CI-AKI in the iodixanol group than in the LOCM group overall (summary RR:
.79, 95% conﬁdence interval [CI]: 0.56 to 1.12, p  0.19). There was no signiﬁcant difference in the
ates of post-procedure hemodialysis or death. There was a reduction in CI-AKI when iodixanol was
ompared with ioxaglate (RR: 0.58, 95% CI: 0.37 to 0.92; p  0.022) and iohexol (RR: 0.19, 95% CI:
.07 to 0.56; p  0.002), but no difference when compared with iopamidol (RR: 1.20, 95% CI: 0.66 to
.18; p  0.55), iopromide (RR: 0.93, 95% CI: 0.47 to 1.85; p  0.84), or ioversol (RR: 0.92, 95% CI:
.60 to 1.39; p  0.68).
onclusions This meta-analysis including 2,763 subjects suggests that iodixanol, when compared
ith LOCM overall, is not associated with less CI-AKI. The relative renal safety of LOCM compared
ith iodixanol may vary based on the speciﬁc type of LOCM. (J Am Coll Cardiol Intv 2009;2:
45–54) © 2009 by the American College of Cardiology Foundation
rom the *University of Michigan School of Medicine, VA Ann Arbor Healthcare System, and †Center for Statistical
onsultation and Research, University of Michigan, Ann Arbor, Michigan; and the ‡University of Miami, Miami, Florida. Dr.
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646ontrast-induced acute kidney injury (CI-AKI) is a common
omplication of intra-arterial and intravenous contrast administra-
ion. As the population ages, the incidence of CI-AKI likely will
ise with the increased referrals for cardiac catheterization and
adiology studies with intravenous contrast and with the increased
revalence of risk factors for CI-AKI, such as chronic kidney
isease, diabetes, and anemia (1–3). CI-AKI typically occurs
ithin the first 48 to 72 h after exposure to intravascular iodinated
ontrast medium. CI-AKI rarely directly results in immediate
eath or the need for immediate hemodialysis, but it is associated
ith increased cost, increased hospital stay, and increased in-
ospital and long-term morbidity and mortality (2,4,5).
Sodium bicarbonate and acetylcysteine have been shown
n multiple studies to prevent CI-AKI, although there is
ignificant heterogeneity among the existing trials (6–9).
revention of CI-AKI with prophylactic hydration and
inimization of total contrast volume are well-established
eans of preventing CI-AKI (10,11).
The choice of the contrast media used may also influence
he risk of CI-AKI. The use of high-osmolar contrast media
esults in more CI-AKI than the more contemporary low-
smolar contrast media (LOCM) or the iso-osmolar contrast
medium, iodixanol (Visipaque,
GE Healthcare, Princeton, New
Jersey) (12,13). Early studies sug-
gested that iodixanol is even less
harmful to renal function than
some types of LOCM are (14,15).
A previous meta-analysis (16)
suggested a dramatic reduction in
CI-AKI with iodixanol when
compared with LOCM. How-
ver, this analysis included trials that were not specifically
esigned to study the incidence of CI-AKI and in which renal
unction was not systematically determined in all patients.
hus, this study was limited by ascertainment bias (17).
These data provided the rationale for the American College of
ardiology/American Heart Association’s revised 2007 guidelines
or the management of patients with unstable angina/non–ST-
levation myocardial infarction, which now give a class IA recom-
endation for the use of iso-osmolar contrast media for coronary
ngiography in patients with chronic kidney disease (18). More
ecently, several larger randomized controlled trials have been
ublished and have shown no difference in CI-AKI when iodixa-
ol was compared with different types of LOCM (19–22). Also,
recent meta-analysis comparing iodixanol to a pool of nonionic
OCM showed no significant reduction in the rates of CI-AKI
23). There are significant pharmacological differences between
arious LOCM agents, and the disparate results of these trials
ay be in part related to the specific LOCM agent used. The
bjective of this systematic review and meta-analysis was to
ntegrate the latest randomized clinical trials to provide a compre-
ensive comparison of the nephrotoxicity of the iso-osmolar agent
bbreviations
nd Acronyms
I  confidence interval
I-AKI  contrast-induced
cute kidney injury
OCM  low-osmolar
ontrast medium/media
R  risk ratioodixanol and the currently available LOCM. wethods
e performed a computerized search to identify relevant
rticles from 1980 through November 30, 2008, using
EDLINE (National Library of Medicine, Bethesda,
aryland), Embase, ISI Web of Knowledge, Google Scholar,
urrent Contents, and International Pharmaceutical Abstracts
atabases, as well as the Cochrane Central Register of Con-
rolled Trials. We used the following keywords: “iso-osmolar,”
iodixanol” (Visipaque, GE Healthcare, Princeton, New Jer-
ey), “low-osmolar,” “iohexol” (Omnipaque, GE Healthcare,
rinceton, New Jersey), “iopamidol” (Isovue, Bracco Diagnos-
ics, Princeton, New Jersey), “iopromide” (Ultravist, Bayer
ealthCare Pharmaceuticals, Montville, New Jersey), “iover-
ol” (Optiray, Tyco, Tyco Healthcare, Mallinckrodt Inc.,
azelwood, Missouri), “iomeprol” (Iomeron, Bracco Diagnos-
ics, Princeton, New Jersey), “nephrotoxicity,” “contrast ne-
hropathy,” “radiocontrast,” “renal failure,” and “randomized.”
bstract lists from the 2006 to 2008 scientific meetings of the
merican Heart Association, the American College of Cardi-
logy, the European Society of Cardiology, and the Transcath-
ter Cardiovascular Therapeutics were viewed. Other Internet-
ased sources of information were also used to identify any
ther studies of interest. When needed, further information on
he trials was obtained from the study investigators.
tudy selection, data extraction, and quality assessment. A
tudy was included if it randomized patients undergoing
ontrast media application to either LOCM or iodixanol, and
f data on renal function were routinely ascertained in all
atients. Data were independently abstracted by 3 reviewers
M.R., P.M., U.T.) and disagreements were resolved by
onsensus. Reviewers were not blinded to study authors or
utcomes. Attempts were made to retrieve the data from the
riginal source in unpublished studies. Baseline demographic,
linical, and procedural characteristics of each trial were re-
orded, including mean age, average contrast volume, prophy-
actic hydration volume, information about sex, diabetes, chronic
idney disease, type of procedure, type of LOCM used, the use of
rophylactic therapies such as acetylcysteine, and the definition of
I-AKI used. We assessed trial quality by evaluating specific
lements of study design (i.e., concealment of allocation during
andomization, intention-to-treat analysis, and blinded assess-
ent of outcome measures), but did not use a quality score given
he limitations inherent to such an approach (24).
nd points, data synthesis, and data analysis. The primary end
oint was the incidence of CI-AKI as defined by each
ndividual study protocol. Secondary end points were the need
or renal replacement therapy and mortality. Data from all the
elected studies were combined to estimate the pooled risk
atios (RR) for iodixanol versus LOCM using a random-effects
odel. Significant between-study heterogeneity was expected
egarding study populations and because different LOCM
ere used as comparators; therefore, a random-effects model
as used to produce across-study summary RR with 95%
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647onfidence intervals (CI). All analyses were performed on an
ntention-to-treat basis. Continuity correction was used when
n event did not occur in 1 group (25). We quantitatively
valuated the presence of heterogeneity across trials with the Q
nd I2 statistics, with an I2 value of 25% indicating low, 50% at
east moderate, and 75% high between-study heterogeneity.
o assess the effect of individual studies on the summary
stimate of effect, we performed an influence analysis, in which
he pooled estimates were recalculated by omitting 1 study at a
ime. Publication bias was tested by plotting a funnel plot, by
ormal testing using rank order correlation and Egger test of
ntercept, and by the Orwin fail-safe N (26–29). Duval-
weedie trim and fill method was used to assess for presence of
nd impact of missing studies (30). An exploratory meta-
egression using a mixed-effect model was performed to assess
he impact of select variables (age, diabetes, baseline renal
unction, contrast volume) on the incidence of CI-AKI.
inally, an omnibus test was used to test the validity of each
ubgroup analysis (31). All analyses were performed using
omprehensive Meta-Analysis software, version 2.0 (Biostat,
nglewood, New Jersey) and Statistical Analysis System soft-
are, release 9.2 for Windows 2002 to 2008 (SAS Institute,
ary, North Carolina).
esults
total of 120 articles were reviewed. Ninety articles were
nitially rejected because they did not directly compare iodixa-
ol and LOCM, or because they did not document renal
unction as an outcome or safety end point. Of the 30
emaining studies, 14 were rejected because they were not
andomized controlled trials. The remaining 16 studies satis-
Figure 1. Flow Diagram of Selection Strategy
Flow diagram depicting the selection strategy for trials used in this meta-analy
contrast media.ed the pre-determined inclusion criteria and were considered
n the analysis (Fig. 1) (15,19–22,32–42). One study has not
een published as a peer-reviewed report yet but was presented
t the Transcatheter Therapeutics 2006 meeting (40).
Table 1 summarizes the characteristics of the 16 trials
ncluded in our analysis. Of the 2,763 subjects, a total of 1,383
ere randomly assigned to iodixanol (Visipaque) and 1,380 to
OCM. Each of the 16 trials was designed as a superiority trial
nd used creatinine change or CI-AKI as a primary or
econdary outcome. Nine of the trials involved coronary
ngiography alone, 1 trial involved coronary or peripheral
ngiography, 1 trial involved peripheral angiography, and 5
nvolved intravenous injection of contrast for computed to-
ography scans. Twelve of the trials (2,266 of 2,763 patients in
he pooled analysis) only included patients with moderate or
evere renal insufficiency, which was variably defined as serum
reatinine1.5 mg/dl and/or creatinine clearance60 ml/min
14,20,33,37,39,40), estimated glomerular filtration rate 60
l/min (19,22), creatinine clearance 60 ml/min (15), serum
reatinine1.7 mg/dl in men and1.5 mg/dl in women (21),
nd serum creatinine1.7 mg/dl (35). Thirteen trials included
atients with diabetes mellitus. Ten trials used prophylactic
ydration and 6 trials used prophylactic acetylcysteine. There
ere no relevant differences noted between the baseline char-
cteristics of the iodixanol and LOCM groups of patients in
ach of the individual trials. The type of LOCM agent used in
ach study was ioxaglate (Hexabrix, Guerbet Group, Villepinte,
rance) (n  4), iopromide (Ultravist, Bayer HealthCare Phar-
aceuticals, Montville, New Jersey) (n  4), iohexol (Om-
ipaque, GE Healthcare) (n  3), iopamidol (Isovue, Bracco
iagnostics) (n 3), ioversol (Optiray, Tyco Healthcare Group,
-AKI  contrast-induced acute kidney injury; LOCM  low-osmolarsis. CI
Table 1. Key Features of Trials Included in the Meta-Analysis
Juergens et al., 2008 (38) Nguyen et al., 2008 (41) PREDICT, 2008 (19) VALOR, 2008 (21) ACTIVE, 2008 (20) CARE, 2007 (22) IMPACT, 2006 (34)
Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM
Subjects, n 91 100 65 61 123 125 156 143 72 76 210 204 76 77
Male, % 79 73 69 62 50 43 45 38 64 76 60 68 67 70
Age, yrs, mean SD 70.2 9.2 69.4 10.2 63.0 11.7 65.8 13.4 68.3 1.99 69.5 10.05 71.1 9.9 72.6 10.2 65.4 12.1 67.1 14.1 70.5 9.9 72.9 9.0 67.0 11.5 67.3 13.0
Diabetes, % 35 46 35 16 100 100 52 52 13 28 44 38 28 19
Baseline SCr, mg/dl 1.61 1.63 1.77 1.75 1.41 1.46 2.0 1.92 1.7 1.7 1.44 1.46 1.5 1.6
eGFR, ml/min/1.73 m2,
mean SD
47.6 16.5 45.6 15 51.8 16.6 53.0 26.0 49.9 11.6 47.6 13.5 36.5 11.3 38.8 11.1 NA NA NA NA NA NA
Mean contrast
volume, ml
101 116 115 100 101.6 106.5 118.4 129.9 125 100 136.4 133.7 125 109
Mean hydration
volume, ml
1,175 1,119 NA NA 928.4 832.5 1,311 1,420 1,369 1,125 11.5
(ml/kg)
11.2
(ml/kg)
644 552
NAC use, % 100 100 12.3 13.1 1.6 2.4 71.1 76.2 0 0 42.3 38.7 0 0
Reason for contrast Coronary angiography CT (IV) CT (IV) Coronary angiography CT (IV) Coronary angiography CT (IV)
Type of LOCM Iopromide Iopromide Iopamidol Ioversol Iomeprol Iopamidol Iopamidol
CI-AKI deﬁnition SCr 1 0.5 mg/dl
or 25%
SCr 1 0.5 mg/dl SCr 1 25% SCr 1 0.5 mg/dl SCr 1 0.5 mg/dl SCr 1 0.5 mg/dl SCr 1 25%
CI-AKI time frame,
days
2 1–3 2–3 3 2–3 3 2–3
Creatinine assessment,
days
2, 7 1, 2, 3 2–3 1, 2, 3 2–3, 7 45–120 (h), 7 2–3
Total patients, N 191 126 248 199 148 414 153
Primary outcome CI-AKI Creatinine change CI-AKI CI-AKI CI-AKI CI-AKI CI-AKI
Feldkamp et al., 2006 (37) ICON, 2006 (40) RECOVER, 2006 (15) NEPHRIC, 2003 (14)
Chalmers and Jackson,
1999 (36) Carraro et al., 1998 (35) Tveit et al., 1994 (42)
Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM
Subjects, n 105 116 71 74 140 135 64 105 116 71 74 140 135 64
Male, % 75 76 87 88 56 56 64 75 76 87 88 56 56 64
Age, yrs, mean  SD 60.6 10.0 62.1 9.2 71.5 9.9 71.3 12.3 66.1 8.6 68.7 7.5 71.1 6.0 60.6 10.0 62.1 9.2 71.5 9.9 71.3 12.3 66.1 8.6 68.7 7.5 71.1 6.0
Diabetes, % 40 35 42 49 34 36 100 40 35 42 49 34 36 100
Baseline SCr, mg/dl 1/04 1.03 1.86 1.8 1.38 1.3 1.49 1/04 1.03 1.86 1.8 1.38 1.3 1.49
eGFR, ml/min/1.73 m2,
mean  SD
NA NA NA NA NA NA NA NA NA NA NA NA NA NA
Mean contrast
volume, ml
1,000 1,000 217 204 204.6 194.8 163 1,000 1,000 217 204 204.6 194.8 163
Mean hydration
volume, ml
1,000 1,000 1,700 1,700 8 (ml/kg) 8 (ml/kg) 977 1,000 1,000 1,700 1,700 8 (ml/kg) 8 (ml/kg) 977
NAC use, % 0 0 NA NA 0 0 NA 0 0 NA NA 0 0 NA
Continued on next page
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Table 1. Continued
Feldkamp et al., 2006 (37) ICON, 2006 (40) RECOVER, 2006 (15) NEPHRIC, 2003 (14)
Chalmers and Jackson,
1999 (36) Carraro et al., 1998 (35) Tveit et al., 1994 (42)
Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM Iodixanol LOCM
Reason for contrast Coronary angiography Coronary angiography Coronary angiography Coronary or peripheral
angiography
Peripheral angiography CT (IV) Coronary angiography
Type of LOCM Iopromide Ioxaglate Ioxaglate Iohexol Iohexol Iopromide Ioxaglate
CI-AKI deﬁnition SCr 1 25% SCr 1 0.5 mg/dl SCr 1 0.5 mg/dl
or 25%
SCr 1 0.5 mg/dl SCr 1 25% SCr 1 50% Not deﬁned
CI-AKI time frame,
days
2 3 2 3 7 1 2
Creatinine assessment,
days
2 1, 2 1, 2 2, 3, 7 1, 2–7 1, 2 ?
Total patients, N 221 145 275 129 102 64 102
Primary outcome CI-AKI Creatinine change CI-AKI Creatinine change CI-AKI CI-AKI Creatinine change
Klow et al., 1993 (39) Andersen et al., 1993 (32)
Iodixanol LOCM Iodixanol LOCM
Subjects, n 35 37 36 38
Male, % NA NA 75 66
Age, yrs, mean  SD 54 9 55 9 54 56
Diabetes, % NA NA NA NA
Baseline SCr, mg/dl NA NA 1.05 0.98
eGFR, ml/min/1.73 m2, mean  SD NA NA 93 9 85 29
Mean contrast volume, ml 175 174 107 106
Mean hydration volume, ml NA NA NA NA
NAC use, % NA NA NA NA
Reason for contrast Coronary angiography Coronary angiography
Type of LOCM Iohexol Ioxaglate
CI-AKI deﬁnition SCr 1 50% GFR 2 25%
CI-AKI time frame, days 2 2
Creatinine assessment, days 1, 2 1, 2
Total patients, N 72 74
Primary outcome Adverse events Adverse events
CI-AKI contrast-induced acute kidney injury; CT (IV) computed tomography (intravenous); eGFR estimated glomerular filtration rate; LOCM low-osmolar contrast media; NA not applicable; NAC N-acetylcysteine; SCr serum creatinine; SD standard
deviation.
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650allinckrodt Inc.) (n  1), and iomeprol (Iomeron, Bracco
iagnostics) (n  1). Ioxaglate is the only ionic dimer included;
he other agents are nonionic monomers. The definition of
I-AKI varied among the trials. Most studies (n  6) defined
I-AKI as an absolute increase of creatinine by at least 0.5 mg/dl
20–22,33,35,41) or as a relative increase by at least 25% (n 4)
19,36,37). A few studies used a composite of the 2 definitions
n 3) (15,34,38,40). One trial used the definition of a relative
ncrease of at least 50% (39), and 2 trials based their definition
n a decrease of glomerular filtration rate of at least 25%
32,42). For each study, we used the corresponding pre-
efined primary end point.
linical end points. CONTRAST-INDUCED ACUTE KIDNEY
NJURY. The primary clinical end point of our meta-analysis
as CI-AKI. There was an overall trend in favor of iodixanol,
ut no significant difference in the overall risk of CI-AKI
etween the iodixanol and the pooled LOCM groups.
I-AKI occurred in 128 of 1,379 patients receiving iodixa-
ol and in 158 of the 1,375 patients assigned to LOCM
reatment (RR: 0.79, 95% CI: 0.56 to 1.12; p 0.189) (Fig.
). There was moderate heterogeneity across studies regard-
ng clinical or patient characteristics and protocols, and also
ccording to formal tests (I2  44.7; Q  23.5, p  0.036).
n influence analysis omitting 1 individual study at a time
o determine if a single study dominated the results of the
ooled analysis did not change the lack of difference
etween iodixanol and the pool of LOCM agents, suggest-
ng that no single individual study overwhelmingly influ-
nced the overall results of the pooled analysis.
Figure 2. Forest Plot of RR of CI-AKI
Forest plot of risk ratios (RR) of contrast-induced acute kidney injury (CI-AKI) of po
patients in the low-osmolar contrast media (LOCM) group  1,289. ACTIVE  Abd
Study; CARE  Cardiac Angiography in Renally Impaired Patients Study; CI  conﬁ
Nephropathy After Angioplasty in Chronic Renal Failure Patients; IMPACT  renall
Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-I
undergoing Computed Tomography; RECOVER  Renal Toxicity Evaluation and Co
going Coronary Angiography; VALOR  Visipaque Angiography/Interventions With LaboIn a subset analysis of the 8 studies involving 1,793
atients in the setting of coronary angiography and inter-
entions, there was no difference in CI-AKI between
atients randomized to iodixanol and LOCM (RR: 0.82,
5% CI: 0.55 to 1.21; p  0.31) (Fig. 3). A subgroup
nalysis limited to data specific for diabetic patients (n 
14, 7 studies) demonstrated similar findings (RR: 0.64,
5% CI: 0.29 to 1.44; p  0.285). Meta-regressions did not
uggest an association between the relative effect of iodixa-
ol and the average baseline creatinine level of each study
slope  –0.029, standard error [SE]: 0.028; p  0.31) or
ny of the other variables studied (data not shown).
A stratified analysis by the specific LOCM explained part of
he observed heterogeneity and demonstrated a relatively lower
isk of CI-AKI with iodixanol than with iohexol (RR: 0.19,
5% CI: 0.07 to 0.56; p 0.002) or ioxaglate (RR: 0.58, 95%
I: 0.37 to 0.92; p  0.022) (Fig. 4). No relative difference in
he risk of CI-AKI was observed between iodixanol and
opamidol (RR: 1.20, 95% CI: 0.66 to 2.18; p  0.55),
opromide (RR: 0.93, 95% CI: 0.47 to 1.85; p  0.84), or
oversol (RR: 0.92, 95% CI: 0.60 to 1.39; p  0.68). Only 1
tudy used iomeprol and thus a pooled analysis was not
erformed, but this is the 1 study that actually shows a higher
ncidence of CI-AKI with iodixanol (20). An omnibus test was
sed to investigate the validity of the subgroup analysis and
onfirmed a significant difference in CI-AKI when comparing
he type of LOCM (p 0.004), but not when comparing the
oute (intravenous vs. intra-arterial, p  0.07) of contrast
dministration.
rials. Total number of patients in iodixanol group  1,291. Total number of
l Computed Tomography: IOMERON 400 versus VISIPAQUE 320 Enhancement
interval; ICON  Ionic Versus Nonionic Contrast to Obviate Worsening
ired PAtients undergoing Computed Tomography; IX  iodixanol; NEPHRIC 
ontrast Media Study; PREDICT  Patients with Renal Impairment and Diabetes
ison Between Visipaque and Hexabrix in Patients With Renal Insufﬁciency Under-oled t
omina
dence
y IMpa
onic C
mparratory Outcomes in Renal Insufﬁciency Study.
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651There was no suspicion of publication bias based on
unnel plot symmetry and according to formal testing (rank
rder correlation or Kendall taub: 0.022, 1-tailed p value:
.48, Egger test intercept: 0.24, 95% CI: 1.83 to 1.35,
-tailed p value: 0.37) (Fig. 5). The classic fail-safe N was
ot valid for our analysis because there was no significant
ifference between the 2 groups; thus, an Orwin fail-safe N
as derived. Using an imputed RR of 0.3 favoring iodixanol
ver LOCM, 15 studies would be required to achieve a
ignificant pooled RR of CI-AKI under 0.5. Using a less
tringent RR of 0.39 as described in the prior meta-analysis
16), 30 such studies would be needed.
Figure 3. Forest Plot of RR of CI-AKI of Patients Undergoing Coronary Ang
Forest plot of risk ratios (RR) of contrast-induced acute kidney injury (CI-AKI) in
iodixanol group  873. Total number of patients in the low-osmolar contrast m
Figure 4. Forest Plot of RR of CI-AKI by Contrast Media
Forest plot of risk ratios of contrast-induced acute kidney injury. Analyses strat
viations as in Figures 2 and 3.EED FOR HEMODIALYSIS. Need for hemodialysis was re-
orded in 12 trials. In 9 of these, no event was observed in
ither of the study arms. A total of 2 patients in the
odixanol arms (n  1,031) required hemodialysis (range:
% to 1.5%), and 9 patients in the LOCM arms (n 1,036;
ange: 0% to 9.2%). This difference was not statistically
ignificant (RR: 0.37, 95% CI: 0.08 to 1.68; p  0.20).
ORTALITY. Data for mortality were available from 9
tudies (n  1,491 patients). No death was recorded in
ither study arm in 6 of these trials. The overall mortality
ate was not significantly different between the 2 treatment
roups: 7 deaths in the 743 patients assigned to iodixanol
hy
es of patients undergoing coronary angiography. Total number of patients in
(LOCM) group  875. Abbreviations as in Figures 1 and 2.
y the different low-osmolar contrast media compared with iodixanol. Abbre-iograp
studiiﬁed b
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652range: 0% to 4.9%) and 5 deaths in the 748 patients
andomized to LOCM (range: 0% to 3.6%), with a sum-
ary RR of 1.38 (95% CI: 0.33 to 5.79, p  0.663).
iscussion
he main finding of this systematic review of the published
tudies and meta-analysis is that there is no significant
ifference in the incidence of CI-AKI when using iodixanol
han when using a pool of ionic and nonionic LOCM. The
ast majority of these trials (12 of 16) included subjects with
levated mean creatinine. Although the inclusion of both
onic and nonionic forms of LOCM as well as of intrave-
ous and intra-arterial contrast injection helps make the
esults of this analysis more generalizable, it should also be
oted that our subgroup analysis of only those trials involv-
ng coronary angiography also does not show a benefit of
odixanol over other LOCM.
A stratified analysis that indirectly compared the various
ypes of LOCM demonstrated that some LOCM are relatively
Figure 5. Funnel Plot of SE by Log RR
Funnel plot of standard error (SE) by log risk ratio (RR), demonstrating absence
Table 2. Key Characteristics of Different Contrast Media
Generation Class Type of Molecule
First High-osmolar Ionic monomer Diatr
Second Low-osmolar Ionic dimer Ioxag
Low-osmolar Nonionic monomer Iopam
Iohex
Iopro
Ioxila
IoverThird Iso-osmolar Nonionic dimer Iodixanol (Vore likely to cause CI-AKI compared with iodixanol than
thers. In our stratified analysis, iodixanol is associated with a
elatively lower rate of CI-AKI when compared with ioxaglate
r iohexol, but there is no relative difference in CI-AKI when
omparing iodixanol with iopromide, iopamidol, iomeprol, or
oversol. This suggests that the risk of CI-AKI cannot be
xplained by osmolarity alone (Table 2). Ionicity is a feature
nique to ioxaglate among the LOCM, and our stratified
nalysis suggests this agent is relatively more likely to result in
I-AKI. Whether viscosity is a significant factor in the risk of
eveloping CI-AKI is not known. In fact, the exact mecha-
ism of CI-AKI is imperfectly established, but it is thought to
nvolve renal medullary hypoxia due to renal artery vasocon-
triction and hyperviscosity or direct renal cytotoxicity from
ontrast agents (43,44).
The lack of significant difference in mortality and need
or hemodialysis between those treated with iodixanol and
hose treated with LOCM is not surprising, given the sheer
nfrequency of this outcome and given that the follow-up in
blication bias.
ples
Iodine
(mg I/ml)
Osmolarity
(mOsm/kg-H2O)
Viscosity
at 37°C
(Hypaque) 370 2,076 8.4
exabrix) 320 600 7.5
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653any of these trials was very short. With that said, even
odest elevations in serum creatinine after contrast expo-
ure are associated with increased long-term morbidity and
ortality. In a retrospective analysis of 9,067 post-PCI
atients, the 1-year survival of patients with renal failure was
0.3% and without renal failure was 93.6% (4).
Although the pooled analysis trended in favor of iodixanol,
his was not statistically significant—a finding that differs from
he results of a previous meta-analysis published by McCul-
ough et al. (16) that indicated that the use of iodixanol is
ssociated with lower rates of CI-AKI than LOCM, particu-
arly in patients with chronic kidney disease and diabetes (16).
he subjects used in the analysis by McCullough et al. (16)
ere taken from a pool of trials that did not explicitly use
I-AKI as an end point, which may have resulted in ascer-
ainment bias and lack of control of confounding variables. In
act, although creatinine typically peaks at 48 to 72 h after
ntravascular contrast exposure, only 40% of the subjects had
reatinine checks at 48 h and less than 20% had creatinine
hecks at 72 h. In addition, 83% of the subjects in the LOCM
rm received ioxaglate or iohexol, both of which were associ-
ted with relatively more CI-AKI in our stratified analysis.
inally, the study by McCullough et al. (16) only included
rials through 2003, and there are several randomized con-
rolled trials published since 2003 that we included in this
urrent study. The data presented here provide an updated and
ore comprehensive look at the nephrotoxicity of iodixanol
ersus various LOCM. We only included trials designed to
ook at CI-AKI as an end point, thus ensuring adequate
ontrol of confounding variables in the 2 study arms and
inimizing the likelihood of ascertainment bias. Our results
orroborate those of a recent meta-analysis that showed no
ignificant difference in the rates of CI-AKI when iodixanol was
ompared with a pool of nonionic LOCM (23). However, our
tudy includes both ionic and nonionic forms of LOCM and
rovides a direct comparison of coronary angiography trials.
The 2007 ACC/AHA guidelines update gives a class IA
ecommendation for the use of iso-osmolar contrast media
or coronary angiography in the setting of unstable angina or
on–ST-segment elevation myocardial infarction and renal
nsufficiency (18). The findings of recent randomized trials
nd of this meta-analysis suggest a revision of this recom-
endation may be in order.
Finally, given the relative lack of difference in CI-AKI with
se of iodixanol and some types of LOCM, cost emerges as an
mportant factor in the choice of which agent to use. Pricing
or LOCM and iodixanol varies among institutions depending
n the size of the contract and the packaging of the materials.
hen considering the vast number of cardiac catheterizations,
eripheral angiography procedures, and computed tomography
cans with intravenous contrast performed each year in the
.S., choosing a less-expensive but equally efficacious agentould result in significant cost-reduction.tudy limitations. Our meta-analysis is subject to the limi-
ations inherent to all meta-analysis. There is a risk of
ublication bias, although this tested nonsignificant in our
tudy. There is possibility of limited power and a type II
tatistical error, but this is unlikely as demonstrated by the
igh Orwin fail-safe number. Also, not all trials reported
tandardizations on hydration or prophylactic medications
sed. Finally, although CI-AKI is associated with worse
ong-term prognosis, the included trials focused primarily
n short-term elevations in creatinine rather than long-term
utcomes of harder end points.
onclusions
his systematic review and meta-analysis demonstrates that the
se of iodixanol, when compared with a pool of LOCM, does not
esult in less nephrotoxicity. There appears to be no difference in
he risk of nephrotoxicity when iodixanol is compared with
opamidol, iopromide, and ioversol, whereas iodixanol appears to
ause less nephrotoxicity than ioxaglate and iohexol do. Further
rials comparing various iso-osmolar and low-osmolar media are
eeded in order to determine the optimal contrast agent for use in
atients with chronic renal insufficiency and the impact of indi-
idual contrast media on long-term outcomes.
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